Insmed | INSM - Sales Revenues

Stock Price
143.70
Daily Change
1.00 0.70%
Monthly
-10.75%
Yearly
82.04%
Q1 Forecast
135.29

Insmed reported $263.8M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Cytokinetics USD 17.76M 15.83M Dec/2025
DBV Technologies USD 2.77M 1.31M Sep/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Novartis USD 14.36B 478M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025